Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Daily observations.
First off, I was wrong in MY OPINION that I didn't think they would raise the AS if they had an ASM this year. That was my own opinion and not a 'Campfire' story. My opinion was purely based on the preferred C-shares and nothing else, which I will talk about below.
In regard to the upcoming ASM, I will vote yes prop 6. I think it is the right thing to do as it is needed at this time. I know several shareholders with a lot more shares than myself and they are all voting to approve the raise in AS. I find it interesting that some of the posters who have been furiously against an R/S have stated they might vote no. That would be guaranteeing that we will see an R/S in the future. The company has even said so much: "the Company needs to either amend the Certificate of Incorporation to increase the number of authorized shares or implement a reverse split of the Common Stock." That could be scare tactics, but those who have read my previous posts, I do not see an R/S as negatively as others when done at the right time. I find it funny we have investors that do not understand the difference between authorized and issued and think the raise is a dilution.
I will also vote yes on the election of directors and likely on the ratification and approval of executive compensation.
In regard to the 500M raise in AS, I think that is a reasonable number. We currently have around a little less that 1.5B shares potentially issued when fully diluted (already issued plus options and warrant liablities). I am not including the 24M potential shares from the sold C-shares, as there's no saying if they would ever be converted. That gives them 200M shares of Common stock that is authorized but not issued. In addition they have the 100M preferred share to play around with, where 10M have been authorized as series C shares. Reviewing the document creating those shares, I saw that they were non-transferable EXCEPT when authorized by the board. I think that in the event of a partnership, they could use the C-shares as the shares to sell to the partner. I think that 10% would be a good percentage of the company for a partner to acquire. That would be just under 8M C-shares. A partner would not have any need to convert those shares to common stock and thus the c-shares would not impede in the 1.7B cap on common stock the company can issue. They would want to keep them as 'preferred' with all the benefits that entail versus common stock. The have the potential, currently, to issue up to 90M additional preferred shares as the articles of incorporation allows for 100M preferred shares in addition to the common stock shares. These could come in handy at a later time.
Personally, I think the ASM announcement is a positive. That is just my opinion. I do not have any idea how the market in general will perceive it. It seems like those fighting against NWBO use every news event to try to move the price lower. I do not know if they will do it this time, but they have proven that they can if they want to. I do think that with the JA out, they are either being careful or there's more support from the market in general. The daily SP is not a concern of mine, so this issue seems irrelevant at this time for me.
I am still not in the camp of a buy out will happen, now or in the near future. The raising of the AS from 1.2B to 1.7B does not in itself preclude it. It would actually be a sign that it was a possibility, due to the fact that after the raise, they will have enough shares to issue which is important in a BO/Merger. BUT the current SP is in my mind a close to 100% guarantee that it won't happen. LP is not selling NWBO at this or anywhere near this level.
I do think that a partnership would still be an option. I have mentioned how I would like to see such a partnership structure and to me that is still the best option. $x upfront. $x for milestones. Maybe $x for x amount of shares (maybe 10% of the company at a price either pre-determined or at a certain date) and a profit sharing for perpetuity (BMY paid NKTR 65% in their setup for exclusive rights for 9 indications). Merck is still my favorite, based on Duffy, the value it can bring to Keytruda and the fact that Keytruda seems to be the checkpoint inhibitor with the best results in most indications. That doesn't exclude others from being in the mix.
I think that at least one thing, if not more, will need to happen before any deal can be announced. We need to get the MIA for Sawston. That is almost a given, as any partner would want to know that commercial production of Murcidencel is in the clear before paying out money for a partnership. I think that could literally happen any day now.
We might also actually have to have the shares available (ASM and a yes vote for raising the AS). If the partner is Merck, they might be waiting for news from the combo trial. I remember that at this time last year, a few posters were hoping for some form of intermediate results. Now that the results of Murcidencel has been announced, it could free up the release of some new about the combo trial. As I am not a scientist, they might have to wait for approval of Murcidencel before they can release any news, but I don't know. I just know that people more involved with the science were hoping for some news last year.
Sorry for the longwinded post. JMHO. I am an easy target to argue with as I am not able to respond. Hope your Thanksgiving was amazing and that we see some positive signs in the near future.
What is happening next week which will require them to square their short positions up?
I hear you Gary, though usually I see all the money go to a development stage company. Money to secondary market shareholders is money wasted, in my opinion, when it needs to be put to use and when that investment will build capacity or find expanding markets. Possible, but I have not seen it as a general practice.
We will vote with you too xoma; we have 25M+ shares in our group. MMs and shorts have to return all the naked shorted shares correcting their books starting next week. MOASS coming next week, imo.
Of course Doc. There are very staunch and stalwart supporters. I agree.
Those attempting to squeeze the price again for whatever reason, are also working to deprive NWBO of capital, make it more costly for the company and other shareholders and ensure more dilution.
It’s a catch 22 that one can seem to be arguing for one thing, while those arguments accomplish the exact opposite. Sometimes that is by chance or accident and sometimes not. Hard to know what.
Re: None
Saturday, November 26, 2022 6:45:25 PM
Post#
539229
of 539241
Gregory Zivic, MD @metacollectiveG
Replying to @edon5 @apwriter
"Silence when it’s appropriate is good. I think we’ve already gotten the manufacturing approval and will hear that this week. That would trigger the MAA submission also. I believe they’ve been using RTOR with the FDA that will shorten that approval about 4 months after MHRA"
metacollectiveG's avatar
Gregory Zivic, MD @metacollectiveG
Replying to @highwayman4life @DoctorStock06
"What I’m getting at is they’ve done everything they’ve told us they’re working on except for marketing approvals. I think they’ve got a plan and have stuck with it and we’re now seeing those results begin. I’d love the sp to be higher but not with PRs that are not meaningful"
metacollectiveG's avatar
Gregory Zivic, MD @metacollectiveG
Replying to @highwayman4life @DoctorStock06
"They have one trial. They finished it, did an absolutely incredible job with the SAP, got it published in a top journal, are about to announce manufacturing approval, and announce a marketing application. What is it you’d add"?
metacollectiveG's avatar
Gregory Zivic, MD @metacollectiveG
Replying to @DoctorStock06
"I believe maybe some sort of buy in outside of BP, say a big biotech fund, to develop the manufacturing both at Sawston and in the US because we’ll get marketing approval in UK by end of first quarter, followed about 4 months later by FDA. Look at RTOR".
metacollectiveG's avatar
Gregory Zivic, MD @metacollectiveG
Replying to @DoctorStock06
"250 million are for fully converted C series shares and 250 million are suspended option shares that only get released with a buy in/buy out. Think it through"
metacollectiveG's avatar
Gregory Zivic, MD @metacollectiveG
Replying to @JonksStonks
"250 million of those are suspended shares that would only come into play with a buy out"
Bullish
BULLISH
Let me quote the part of the court case that I have quoted to you many times ExW:
A review of the record in its entirety leaves as the only reasonable inference that the data monitoring committee had reviewed only safety data from the Phase III trials, not efficacy data.
Bio - I totally agree with you.
Timing the market is hard and those who sold and hoping to get back in are changing tune.
Our team continue to hold and accumulate whenever possible.
We will be voting “YES” with over 5+ million.
Mr Smokey, hope you will vote with us.
Stay long and be richly rewarded.
biosectinvestor,
No need to worry. Those who are invested here for more than just the money will vote with Linda no matter what as will many who understand the opportunity and situation business wise. Linda will get the word out about the importance of the vote and any additional news would seal it. This situation is different than in the past and HappyLibrarian’s position exemplifies the impact of the progress made to date. In the past I would have pushed back more against posts expressing angst because of the impact that a let down could create. Not going to happen like that anymore. Best wishes.
how did you get a long convo with DI if you only have 60k shares? I want one...ive got more!!
“NWBO may be disruptive, but is also uniquely inclusive.”
That is a spot on statement. Lots of power in those words if you really stop to think of what it can mean. “Can” mean. This egg is hatching now. I hope everyone is careful not to accidentally step on it.
I don't believe the suspended options only apply with a buy-in or buyout, I believe they'll be converted to shares as soon as sufficient shares have been authorized to do so. Once the additional shares are authorized I suspect you'll see these shares converted and the company will receive somewhere around $75 million as they are, though it may be less if some choose to take the cashless option. I could be wrong, but believe that most of these shares not held by management are held by wealthier investors who can afford to pay for their options to be converted to shares. If I'm right about this, the company shouldn't be in an immediate hurt for funds, they can take their time before either an offering, or a partnership.
Gary
I am not sure the arguments you dismiss actually are incorrect. I accepted your word that it said something else, because I was busy, but this what the updated SAP, the one filed with the JAMA article says, as of 2020:
https://cdn.jamanetwork.com/ama/content_public/journal/oncology/0/coi220066supp1_prod_1668698380.81699.pdf?Expires=1672467457&Signature=zgLfN4HC0StuPpHTf0OoemUxdrjV5nF2ua0hWbx6kwO5IgflPmMDt4ZWtvQkbHGysZ6UXDQdFRCdOO8Mxer8zwO9BThHxqlZRF4TmE8ro1cuEbxZ51gj0prZll54ovBHW6Qm5v1PC5OPLdHJNBIe0On5JGc9wyR5NfcMzFNQswx~UY3WfYN9rIR8I3zusvDQ~mBoMojnALQ6VzH3RTq-2lPA2tm1cnhosPwaiXNZ~LxA5UaJx1UU1Pnwm9KBySil3evc~rZRgef34mp4I5DekyZqjmoVzXbNce5bJRcABOj4GNDgbRs7Az5LeMObEhjVNeCzQ9U~7S857xFWU3cmHA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA
1.4. Interim analysis
The original trial protocol specified the following interim analyses:
Two interim analyses for PFS were to be performed. The first was to occur after approximately 60% of the expected PFS events (i.e. 149 events) had occurred; the second after approximately 80% of the expected PFS events (i.e. 198 events) had occurred. In practice, one interim analysis was conducted. Group sequential methods were to be used for these analyses to control the Type I error rate. Critical values for interim testing were to be calculated using the method of Lan-DeMets and an O'Brien-Fleming spending function. The significance levels at the interim and final analyses were to be calculated using the O’Brien-Fleming alpha spending function:
??
???????????? ?? ???
where a=0.05 is the overall (2 sided) significance level and t^* is the proportion of the total events that occurred until the time of the interim analysis.
iii. Interim Analysis of DCVax–L Phase III Trial by DSMB
Plaintiffs next allege that Defendants' statements made in the March 7, 2014 press release, April 1, 2014 annual report on Form 10–K, and December 10, 2014 Oppenheimer 25th Annual Health Conference regarding the interim analysis by the DSMB were materially false or misleading. ECF No. 22 ¶¶ 54, 56, 76. Plaintiffs allege that "the review of efficacy data by the DSMB was not pending and would easily have been completed" and Defendants "omitted that the Company did not need a formal interim analysis to make a ballpark assessment of efficacy." ¶ 52. Plaintiffs further state that "the assertion that the analysis remained ‘outstanding’ falsely implied that it was in the process of being completed, when in fact it was either completed and buried, or the DSMB had been directed not to complete it." Id. ¶ 57. Plaintiffs also claim, with respect to the January 12, 2015 remarks, that "the interim review was not scheduled to commence in 2015 but in fact had commenced in 2013 and required only a few weeks to complete." Id. ¶ 79.
It first bears noting that Plaintiffs cite to a December 13, 2013 press release which explicitly states, "The Company does not participate in the interim analysis process or the assessment, and both the Company and the clinical trial sites remain completely blinded." ECF No. 26–6 at 5. Thus, it is unclear from the Complaint how Plaintiffs attribute the alleged shortcomings of the safety board review to Defendants given their stated lack of involvement. But more importantly, Plaintiffs rely on the unfounded "expert" opinion of Dr. Richard A. Guarino for their contention that "there is absolutely no reason why an interim analysis could not be completed within a few weeks." ECF No. 22 ¶ 47. Plaintiffs may not substitute factual allegations with the speculation of their expert witness. See Fin. Acquisition Partners LP v. Blackwell , 440 F.3d 278, 285–86 (5th Cir. 2006) ("allowing plaintiffs to rely on an expert's opinion in order to state securities claims requires a court to ‘confront a myriad of complex evidentiary issues not generally capable of resolution at the pleading stage.’ In addition, considering such opinions might require ruling on the expert's qualifications."); DeMarco v. DepoTech Corp., 149 F.Supp.2d 1212, 1222 (S.D. Cal. 2001) ("Conclusory allegations and speculation carry no additional weight merely because a plaintiff placed them within the affidavit of a retained expert.").
The gravamen of Plaintiffs' objections regarding the interim review by DSMB appears to be that it took too long, or that Defendants somehow delayed announcing conclusive results, or concealed the results altogether. But "Defendants, like any other company wishing to publicly discuss the results of a scientific study, had to make a judgment as to which specific bits of information about the study and its conclusions to disclose." Padnes v. Scios Nova Inc., No. C 95-1693 MHP, 1996 WL 539711, at *5 (N.D. Cal. Sept. 18, 1996) ; see also In re Human Genome Scis. Inc. Sec. Litig., 933 F.Supp.2d 751, 761 (D. Md. 2013) (noting that "[w]hile it is possible to infer that ... executives deliberately omitted facts ... in order to hoodwink investors, it is just as plausible, indeed more so, to infer that they only offered vague details about the study because it was ongoing."). Plaintiffs here do not "plead facts sufficient to explain why the defendants' summaries [or lack thereof] of the study were false or misleading." In re Rigel , 697 F.3d at 879. Plaintiffs' additional argument that Defendants were trying to "bury" interim efficacy results is undercut by the record itself. A review of the record in its entirety leaves as the only reasonable inference that the data monitoring committee had reviewed only safety data from the Phase III trials, not efficacy data. ECF No. 22 at 34 ("We had a safety-only evaluation ... by the Data Safety Monitoring Committee"); 35 ("Up to now the assessments have only been safety, so this will be the first assessment for efficacy"). Plaintiffs do not establish how Defendants deliberately withheld or concealed information with respect to the interim review.
Accordingly, Plaintiffs' claims related to the Interim Analysis of the DCVax–L Phase III Trial by the DSMB are dismissed.
Started accumulating when SP was around $1.7. Last week increased the position by 20% at $1.1. So I had no sound strategy. But still happy since I didn't miss the train.
PM,
Could you include in your training syllabus on how to handle a scenario like this?
Correction, yes earlier proxies have the same language, so it’s nothing special as you note. Should have said that’s the kind of scenario the adjournment language might apply, if a special meeting was required prior to the ASM.
Harvey Tran, M.D. @DrTranBioSci
"In one sentence, what is the reason like you $NWBO"?
Michael Bigger
@biggercapital
Replying to @DrTranBioSci
"All Solid Tumors! $NWBO"
Gregory Zivic, MD @metacollectiveG
Replying to @edon5 @apwriter
"Silence when it’s appropriate is good. I think we’ve already gotten the manufacturing approval and will hear that this week. That would trigger the MAA submission also. I believe they’ve been using RTOR with the FDA that will shorten that approval about 4 months after MHRA"
metacollectiveG's avatar
Gregory Zivic, MD @metacollectiveG
Replying to @highwayman4life @DoctorStock06
"What I’m getting at is they’ve done everything they’ve told us they’re working on except for marketing approvals. I think they’ve got a plan and have stuck with it and we’re now seeing those results begin. I’d love the sp to be higher but not with PRs that are not meaningful"
metacollectiveG's avatar
Gregory Zivic, MD @metacollectiveG
Replying to @highwayman4life @DoctorStock06
"They have one trial. They finished it, did an absolutely incredible job with the SAP, got it published in a top journal, are about to announce manufacturing approval, and announce a marketing application. What is it you’d add"?
metacollectiveG's avatar
Gregory Zivic, MD @metacollectiveG
Replying to @DoctorStock06
"I believe maybe some sort of buy in outside of BP, say a big biotech fund, to develop the manufacturing both at Sawston and in the US because we’ll get marketing approval in UK by end of first quarter, followed about 4 months later by FDA. Look at RTOR".
metacollectiveG's avatar
Gregory Zivic, MD @metacollectiveG
Replying to @DoctorStock06
"250 million are for fully converted C series shares and 250 million are suspended option shares that only get released with a buy in/buy out. Think it through"
metacollectiveG's avatar
Gregory Zivic, MD @metacollectiveG
Replying to @JonksStonks
"250 million of those are suspended shares that would only come into play with a buy out"
dstock, MHRA will approve first, FDA then will fall in line.
If a buyout was on the table, why would they need a lot more shares? That doesn’t make sense. The buyer wants your shares and mine. The company does need to issue shares to investors who are owed shares, if any, and also to negotiate and keep things going, particularly if the buyout is only triggered on a still pending event like approval of the commercial license, filing of the marketing application or having it approved.
And as for what someone said about Project Orbis, the U.K. ILAP program would make them eligible to enter that program on the referral of the MHRA for the UK. There is no indication from this filing that suddenly that is “not” in potential play.
Senti, the stock is trading at less than 90 cents per share. No financial investor such as a private equity group is paying $5 per common share fully diluted. Only a strategic investor like a BP will pay that type of premium, and that means they’re looking for synergies with their own business, including partnerships and some level of governance and control.
I have no idea, but the same shorts were saying they had already sold 1.5 billion shares and were over their allocation for years… then Tim hey adjusted maybe 1.2 billion sold. Whatever the case, the latest number I have seen as issues is 1.05 billion not including the outstanding obligations to warrant holders, preferred c, etc.
Yes, if the price goes up, since this is only an authorization, they won’t have to issue as many shares.
I think their authorization request at this life cycle stage of a company with this complex of a product, is very reasonable and wise. I think sophisticated new money will understand the potential and the reasonableness of that request. That they did not go for a reverse split, which some who claimed to want that had promoted here for some time, was also a positive. I would have supported it but many shareholders are challenged by those. It was not asked for, and that says to me that they may have other plans to lift the price up. You may think otherwise but I tend to think LP and team are more wise about these things and have more information than most bulletin board posters.
It also may not help to reveal all secrets. The successful journal article was very positive. I think it is more likely they will have deals than not, and that it will be competitive. Any BP that snoozes, at this time, may very well lose. I think others know this too. This is a critical time for certain parties to be in the mix and working out how they can be the most critical party to help get this successfully to market. Talking it down, before such news hits may be imperative for some who watch this stock.
$NWBO ASM speculation is fun to read. Real value is the technology’s leverage in providing value to partner(s) snd patients.
— Justin Keister MS DABR (@justinkeister5) November 26, 2022
Almost never does an effective, non toxic, symbiotic therapy for cancer hit the market. It’s hard to value things that are almost priceless.
Henry Retweeted
Jordan Shlain MD
@DrShlain
Brain Cancer Update: Phase 3 Clinical Trial: Brain Cancer Vaccine Shows Promising Results
#braincancer
King's College London
https://twitter.com/DrShlain/status/1596605380804902912
Beartrap,
I don't think it matters whether we have the Preferred C's or authorized shares to bargain with, but I don't believe a potential partner would take Preferred shares if it took a vote of the shareholders to cash them in by converting them to normal shares. I believe the Preferreds have been a vehicle for LP to gain some operating funds from friendly investors to keep the company running, while she avoids converting a loan to shares at very cheap share prices by doing a conventional offering.
I'm not suggesting that a potential partner wouldn't take preferreds, but only if they know the company has sufficient shares authorized to convert them. I can see smaller partnerships intended primarily to try DCVax-L and/or Direct with an existing therapeutic owned by the partner, such as Keytruda.
I think it's also equally possible to get a large partnership with a BP where it's their intent to utilize their therapeutics with the DCVax's while making it difficult, or far more expensive, for competitors to do the same.
I believe that in trials intended to improve the performance of the products being tested, both companies will provide products for the trial, and depending on the terms, both may fund the trial. On the other hand if NWBO partnered with say Merck, but Pfizer wished to try their drug with the DCVax's, not only might NWBO not participate in the trial financially, but they could also insist that Pfizer pay retail list price for all the DCVax product required for the trial. If Pfizer did pay, and if their drug had synergies with the DCVax's it would help increase NWBO sales, which would have benefits for Merck, but it would come with no cost to either company.
I believe that LP wants more than $5 per share for such partnerships, I think she wants double digits and that cannot occur until our share price is in the $5+ range by conventional wisdom. All this can happen in a matter of months, but we need the overall share increase authorized, we need the FlaskWorks unit approved for commercial production, then anything is possible. If these things are done, the $5 share price could come before, or after we have regulatory approval from one or more of the regulators.
I frankly have no idea how close we may be to having the FlaskWorks unit approved, or if it is, will it be by all four regulators together, or will each regulator act independently. Of course the regulators must approve the entire commercial production facility, but I believe that several facilities exist that have the equipment needed to supply the vaccine if several of the FlaskWorks units are installed or added to the facilities. I don't believe that CRL, Advent, or anyone else will add the FlaskWorks units until they know they're accepted by the appropriate regulator.
I may be exaggerating, but I believe that adding the FlaskWorks unit is rather like adding printers to a network. It must go in a properly prepared space and have proper power, atmospheric control, etc. but most existing large clean rooms should be able to support several FlaskWorks units and I believe the likes of CRL have many such clean rooms. I believe that both NWBO and St. Gobain's Glass are prepared to build numerous units and disposable cassettes when they're approved for commercial use.
Gary
Hi Legend, this issue actually has been discussed on this board for a long time, as if it had already happened, perhaps falsely.
But even if some suggested, perhaps falsely, that they had obligations to issue shares that were not authorized, the reality is many of us have been discussing this and what was likely at the ASM for a long time.
1) we knew they would need more shares;
2) basically any company with this long of a development stage runway, that hits approval and commercialization stage is going to need capital, potentially lots. I think most informed people here thought they would ask for a billion, given discussions of potential overhang with warrants and then most recently with the preferred C, if they were going to use them to raise money.
3) this was no secret, and for new investors in companies at this stage, you need to understand and create your awareness of such issues through the life of your investment.
As I said, I would have expected probably a billion share authorization. Authorization is not ISSUED. It’s a checkbook. Bankrupt companies are companies that have no shares to offer, and no income. Shareholders are at the very, very bottom of any bankruptcy and even a re-org, are scrunched down to nothing BY LAW.
The fact is, people here chose to invest in this endeavor. It has taken a long time, understandably so even if some will not concede that for whatever reason. It is at the inflection point moving toward potential deals and revenues, and there are the same disgruntled set trying to sabotage it. It tells me more about those people and their interests than the company.
As for what is ahead. Look at the age of the board, not to be ageist. They do not look like they want to raise a huge sum of money with shares to me.
I think they are likely discussing deals, and that would make sense with the paper as it was and the nature of deals for companies at this stage if their development. Do I KNOW this? No. Do I know they will get terms they find acceptable? No, I do not.
It seems like they may think so however, and if not, they probably have enough to continue until they get the offer they want, while proving DCVax’ value.
But I think they have told us they expect deals and might even have inked one already. I find it funny that some who said they were behaving as if they had a deal already, and now when there seems to be further indication that they are likely in a good place to consummate a possible deal, those same persons are suddenly … nope, no deal any time in the foreseeable future. Bad, bad, bad…
As I said, the commentary tells one more about commentators than the company in many instances. Do they need more shares? Were they taken by surprise? What’s the real deal? Some people were strongly predicting a reverse split. So some may have gotten out waiting for that to occur and then buy on the dip. They may have miscalculated.
annie post
@apwriter
"Wow!!! Re : $nwbo ... 44k subscribers"...
Wow!!! Re : $nwbo ... 44k subscribers...
— annie post (@apwriter) November 26, 2022
THIS PENNY STOCK IS HUGE! Set To Explode For Big Gains - YouTube https://t.co/4x1KyPOrPo
Very well said, Beartrap !! I love the way all of us keep accentuating the positive and expanding the narrative!!!
Cheers,
BB
Wow, that’s longevity! I was there in 2018 and 2019, he’s gone now. Probably invested in Apple and retired.
He was a funny guy. He was there as late as 2010 or so, so his act definitely worked out for him.
Michael Bigger Retweeted
Dr. Thomas Ichim
@exosome
I am such a moron…I was tweeting about how awesome $nwbo is but I didn’t even see this paper …what fantastic results !!!
— Dr. Thomas Ichim (@exosome) November 25, 2022
This is hugehttps://t.co/0Y5cYRsuh8
Exactly, the debate has been going on since the last increase was voted on. At least this time we got some news before the vote.
Poor Man, I remember the guy with the bush by Fisherman’s Wharf! It was probably late 80’s to early 90’s. He was a riot. Amazing how many people walked by without noticing him squatting behind a few small branches he held in his hand.
Great, Great post, Bio!!! AND whomever this guy is that you're replying to sounds like he's desperate for relevance!!! But guess what????
Cheers,
BB
Nah, the dude was too athletic.
I would like to thank everyone for all your dd , thoughts,experience and positive incentive.I love to listen to everyones ideas and possible direction this company can be going.I wish fireman 02360 would come back on here and give his thoughts because he has sounded like he knows something great that will be happening here soon.
I love happy endings!
Sure but with so of 90 cents how big of N offer can there really be? Even 5x is still not reasonable in terms of true valuation but probably more than than is typically offered.
Thanks, Biosectinvestor, for explaining naked shorting responsibility in more detail!
That dude jumping out from behind bushes to scare tourists, to separate them from their money, could it have been AF ?
That’s what you’re noticing.
Poor Man -,
Linda Powers lives by leverage. She never gives it up. She believes she will have the votes and I completely agree as long as there is a manufacturing update. That alone makes sure the hurdle is cleared. Without that probably too close for comfort but still possible if not likely because most longs have waited too long to give up on what they know is a winner and almost all will get called and reminded. Best wishes.
Absolutely, Gary and my short piece was meant for today. As in my post the other day when I compared DCVax-L to the first barrel of oil produced and little was known about refining that over time, expanded the market to uses that improve almost everything we do in life.I predict the same will be true for DCVax-L and its successors that will build the "Age of Immunotherapy" in all living things.!!! As my Dad used to say,"That which seems highly improbable is merely beyond the reach of one's imagination!!!"
Cheers,
BB
My recollection is that this board had certainly discussed the probable raising of the AS from a good while ago and even commented, as now, that it would need to be coupled with achieving good news as we have now.
The negative narratives have been recycled over time as well, prompting repetition of the debunking as well.
It was lovely after the JA was published in the JAMA Oncology because the negative posts were suspended for a day or two.
The last time I was at Fisherman’s Wharf, there’s some dude that kept jumping out from behind a bush to scare (entertain?) tourists, and then asks for money. I liked his gig, but a bit risky to use in my park — might get capped-out in my neighborhood.
The custom fit the Dec 30 ASM will be either George Washington or Old Man Time, depending on circumstances.
You probably don't need to eat cup noodle and sleep on the bench anymore....
LG once said they would sell the company if there was an offer on the table they couldn’t refuse. Maybe that’s why there’s adjournment language in the proxy?
Today, a gentleman traveling wearing tights and a buttoned coat with a curly hat atop curly silver hair, wouldn’t get a second look
In fact I encountered a couple of revolutionary characters wearing red coats and triangle hats in San Francisco while I was on a business trip in the late 1970’s, along with a trumpet player in a full gorilla suit at Fisherman’s Wharf!
Followers
|
1627
|
Posters
|
|
Posts (Today)
|
70
|
Posts (Total)
|
704146
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |